Cormark ups Transition price target 52%

Cormark Securities raised its target price on “buy-rated” Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) to $8 from $5.25, saying it believes Irish partner Elan is likely to move Transition’s ELND005 drug forward into a Phase 3 clinical trial in Alzheimer’s disease.  The stock closed at $3.50 on the TSX Friday. An imbalance of deaths in an ongoing [...]

Transition buys rights to a series of preclinical diabetes assets from Lilly

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has expanded its existing relationship with Eli Lilly (NYSE: LLY) by acquiring rights to a series of preclinical diabetes compounds from Lilly under a new licensing and collaboration agreement. Under the accord, Transition will pay Lilly $1 million (U.S.) and Lilly will retain an option to reacquire rights to the compounds [...]

Transition posts positive Phase 2 diabetes results

Transition Therapeutics (TSX:TTH; NASDAQ:TTHI) has reported positive results with type 2 diabetic patients in a Phase 2 clinical study of its gastrin analogue, TT-223 drug. Patients who received the highest daily dose of TT-223 for 12 weeks and completed the entire study without adjusting their diabetes therapies had a “statistically significant” reduction in HbA1c of [...]

In conversation with Maher Yaghi

As Desjardins Securities’ healthcare and biotech analyst for the past five years, Maher Yaghi has gained a wide following with a blunt, tell-it-like-it-is approach to covering a sector that has struggled to win the hearts and minds of investors in recent years.  His early research and “buy” recommendations on Theratechnologies and Paladin Labs established his [...]